GlassScriptPhysician profile
Coy Peters
NPI 1164841557
$9,575.18
in general payments reported to CMS, 2019-2025
42 companies · $1,591 in 2025
The $1,591 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,033 · 2020: $1,475 · 2021: $1,488 · 2022: $1,452 · 2023: $1,215 · 2024: $1,321 · 2025: $1,591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,127.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,113.45 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,099.18 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $1,003.51 | 2019-2025 | |
| Novo Nordisk INC | $986.20 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Lilly USA, LLC | $881.80 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $430.00 | 2019-2025 | Airsupra, Farxiga |
| Amgen INC. | $422.11 | 2019-2025 | Evenity, Repatha, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $411.20 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $361.92 | 2020-2025 | Xarelto, Spravato |
| Merck Sharp & Dohme LLC | $308.81 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Abbott Laboratories | $283.96 | 2020-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $221.71 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $209.40 | 2022-2025 | |
| Allergan, INC. | $202.64 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $175.78 | 2020-2025 | Xifaxan |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Coy Peters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.